Sumitomo Mitsui Trust Group, Inc. 13D and 13G filings for Arcturus Therapeutics Holdings Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-25 06:18 am Sale |
2025-03-31 | 13G | Arcturus Therapeutics Holdings Inc. ARCT |
Sumitomo Mitsui Trust Group, Inc. | 1,926,084 7.100% |
-389,210 (-16.81%) |
Filing |
| 2024-11-05 06:07 am Purchase |
2024-09-30 | 13G | Arcturus Therapeutics Holdings Inc. ARCT |
Sumitomo Mitsui Trust Group, Inc. | 2,315,294 8.560% |
994,642 (+75.31%) |
Filing |
| 2024-02-05 06:08 am Sale |
2023-12-31 | 13G | Arcturus Therapeutics Holdings Inc. ARCT |
Sumitomo Mitsui Trust Group, Inc. | 1,320,652 4.940% |
-128,408 (-8.86%) |
Filing |
| 2023-02-03 06:10 am Purchase |
2022-12-31 | 13G | Arcturus Therapeutics Holdings Inc. ARCT |
Sumitomo Mitsui Trust Group, Inc. | 1,449,060 5.450% |
91,588 (+6.75%) |
Filing |
| 2022-02-04 06:05 am Purchase |
2021-12-31 | 13G | Arcturus Therapeutics Holdings Inc. ARCT |
Sumitomo Mitsui Trust Group, Inc. | 1,357,472 5.140% |
1,357,472 (New Position) |
Filing |